[
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 1,
    "category": "Document Name"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 3,
    "category": "Agreement Date"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 4,
    "category": "Effective Date"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Exhibit 10.5",
    "bbox": [
      1000,
      80,
      1000,
      92
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.",
    "bbox": [
      112,
      129,
      794,
      140
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "SPONSORED RESEARCH AND LICENSE AGREEMENT",
    "bbox": [
      445,
      144,
      885,
      155
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "This Sponsored Research and License Agreement (this \"Agreement') is entered into on November 28, 2018 (the \"Effective Date'), by and",
    "bbox": [
      179,
      160,
      1000,
      173
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (\"ArTara'), and The University of Iowa, located at c/o Division of.",
    "bbox": [
      111,
      179,
      1000,
      193
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (\"University'). ArTara and University may individually be referred to herein as a \"Party,'",
    "bbox": [
      111,
      196,
      1000,
      209
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "and collectively as \"Parties.\"",
    "bbox": [
      112,
      212,
      329,
      224
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WI T N E S SE T H:",
    "bbox": [
      591,
      229,
      743,
      239
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, ArTara is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;",
    "bbox": [
      179,
      244,
      1000,
      257
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, University is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as.",
    "bbox": [
      179,
      259,
      1000,
      274
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "defined below), a pharmaceutical product not approved by regulatory authorities in the United States;.",
    "bbox": [
      111,
      276,
      877,
      289
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAs, University is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1.",
    "bbox": [
      179,
      291,
      1000,
      306
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Nihonbashi 2-Chome, Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite.",
    "bbox": [
      110,
      308,
      1000,
      321
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "3100, Berkeley Heights, New Jersey 07922 (collectively \"Chugai\"), the product manufacturer;.",
    "bbox": [
      111,
      324,
      808,
      337
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAs, Principal Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined",
    "bbox": [
      179,
      341,
      1000,
      353
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "below) approved by the FDA (as defined below) for OK-432 under BB-IND#5266;",
    "bbox": [
      111,
      357,
      722,
      369
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, ArTara wishes to develop and submit for regulatory approval, TARA-o02, a proposed product that will be biosimilar to OK-",
    "bbox": [
      179,
      372,
      1000,
      385
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "432;",
    "bbox": [
      109,
      386,
      149,
      402
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, ArTara wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data",
    "bbox": [
      180,
      404,
      1000,
      417
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "and potentially rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-o02 in the Territory (as defined below);",
    "bbox": [
      113,
      421,
      1000,
      433
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "and",
    "bbox": [
      111,
      436,
      142,
      448
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, the copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of",
    "bbox": [
      179,
      452,
      1000,
      465
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "mutual interest and benefit to University and ArTara.",
    "bbox": [
      111,
      469,
      508,
      480
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties",
    "bbox": [
      178,
      484,
      1000,
      497
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "agree as follows:",
    "bbox": [
      111,
      502,
      236,
      512
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "ARTICLE ONE",
    "bbox": [
      609,
      517,
      724,
      527
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      610,
      533,
      723,
      543
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1",
    "bbox": [
      109,
      547,
      134,
      561
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "\"Affiliates\"' of a person or entity means any other entity which (directly or indirectly) is controlled by, controls or is under common control",
    "bbox": [
      179,
      548,
      1000,
      561
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "\"controlled by' and \"under common control with'') as used with respect to an entity will mean (i) in the case of a corporate entity, direct or",
    "bbox": [
      179,
      580,
      1000,
      593
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case",
    "bbox": [
      179,
      597,
      1000,
      609
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the",
    "bbox": [
      179,
      613,
      1000,
      625
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "management and policies of such entity, provided that if local law restricts foreign ownership, control will be established by direct or",
    "bbox": [
      179,
      628,
      1000,
      640
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests..",
    "bbox": [
      179,
      645,
      1000,
      657
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1",
    "bbox": [
      662,
      677,
      672,
      686
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: ARTARA THERAPEUTICS, INC., 8-K, 1/10/2020",
    "bbox": [
      133,
      1000,
      570,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  }
]